文献速递临床免疫质量管理与危急值

血清前列腺特异性抗原早期检测前列腺癌:弥合临床与实验室实践之间的差距

Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice.
PubMed 文献 · Clin Chem · 2021-01-01

该综述批判性评估了不同商用方法检测总PSA结果的可互换性,讨论了测量物异质性、方法间偏倚及免疫分析设计选择性对PSA诊断准确性的影响,指出当前临床实践指南忽视了实验室问题,并提出填补差距的四个方向。

要点

  • 不同商用PSA检测方法结果可互换性差,当前指南对此忽视。
  • 测量物异质性、方法间偏倚及免疫分析设计影响PSA阈值诊断准确性。
  • 需制备可交换参考材料、提供分析特性、推导基于结局的分析性能规范。

核心结论

  • 当前临床实践指南忽视了不同检测方法PSA结果的可互换性差及实验室问题对PSA检测临床性能的重要影响。

研究设计与样本

  • 综述性文章,批判性评估现有文献中关于不同商用方法检测总PSA结果可互换性的证据来源。

主要发现

  • 测量物异质性、方法间偏倚以及免疫分析的设计和选择性可能影响所选PSA阈值的诊断准确性。
  • 了解在役检测的分析特性(如识别的PSA循环形式及与PSA同源物的交叉反应性)是改善癌症筛查临床决策和个体结果解读可靠性的基础。

临床怎么用

  • 涉及的利益相关者应通过以下方式填补差距:制备可交换的免疫分析校准参考材料;提供可解释检测性能差异的分析特性;推导基于结局的PSA测量分析性能规范;在制定临床实践指南时更多关注实验室项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current clinical practice guidelines (CPGs) for early detection of prostate cancer recommend for clinical decision-making a personalized prostate-specific antigen (PSA)-based management to improve the risk-benefit ratio of the screening strategy. Some important critical issues regarding the PSA determination in the clinical framework are, however, still neglected in current guidelines and a major focus of recommendations on those aspects would be needed to improve their effectiveness. CONTENT: Evidence sources in the available literature concerning the interchangeability of total PSA results measured with different commercial methods were critically appraised. We discuss how the heterogeneity of the measurand, the intermethod bias, and the design and selectivity of immunoassays may affect the diagnostic accuracy of selected PSA thresholds, and how knowledge of the analytical characteristics of assays in service, such as the recognized PSA circulating forms and the cross-reactivity with PSA homologs, is basic for improving both clinical decision-making in cancer screening and the reliability of the clinical interpretation of results at the individual level. SUMMARY: Current CPGs ignore the poor interchangeability of PSA results obtained from different assays and the substantial role of laboratory issues in clinical performance of PSA testing. Involved stakeholders should contribute to fill the existing gap by: (a) preparing commutable reference materials for immunoassay calibration; (b) providing analytical characteristics that may explain the different performance of assays; (c) deriving outcome-based analytical performance specifications for PSA measurement; and (d) giving more focus on laboratory items when CPGs are prepared.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Ferraro S, Bussetti M, Panteghini M, et al. Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. Clin Chem. 2021. PMID: 33619518. doi:10.1093/clinchem/hvab002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。